Long Term Extension Study of Tofacitinib in Refractory Dermatomyositis.
Julie J PaikMatthew ShneydermanLaura Gutierrez-AlamilloJemima AlbaydaEleni TiniakouJamie PerinGrazyna PurwinSherry LeungDoris LeungLivia A Casciola-RosenAndrew S KoenigLisa Christopher-StinePublished in: Arthritis & rheumatology (Hoboken, N.J.) (2021)
We previously demonstrated that tofacitinib was effective in treating skin-predominant refractory dermatomyositis (DM) at 12 weeks in a prospective open label clinical trial, Study of Tofacitinib In Refractory dermatomyositis (STIR) (1). Here, we report the long-term extension results of up to 96 weeks to investigate the treatment durability of tofacitinib in refractory DM. Inclusion criteria and outcome measures were the same as the parent study (1). Assessments were conducted at weeks 20, 72, and 96. The baseline demographic features of all 10 trial patients were reported previously (1).
Keyphrases
- clinical trial
- rheumatoid arthritis
- open label
- interstitial lung disease
- study protocol
- phase ii
- disease activity
- type diabetes
- randomized controlled trial
- ejection fraction
- systemic lupus erythematosus
- metabolic syndrome
- skeletal muscle
- gestational age
- prognostic factors
- systemic sclerosis
- idiopathic pulmonary fibrosis
- double blind